卵巢癌统计学,2018年
美国癌症协会基于全国人群癌症登记发病数据与国家卫生统计中心死亡数据,概述美国卵巢癌发生情况并回顾早期检测策略。2018年美国预计新发22,240例、死亡14,070例;1985至2014年发病率下降29%,1976至2015年死亡率下降33%。
要点
- 2018年美国预计卵巢癌新发22,240例、死亡14,070例。
- 发病率1985至2014年下降29%,死亡率1976至2015年下降33%。
- 非西班牙裔黑人几乎所有分期生存最低,且生存改善停滞。
核心结论
- 美国卵巢癌发病率与死亡率长期下降,但存在显著种族差异,非西班牙裔黑人生存最低且数十年停滞。
研究设计与样本
- 美国癌症协会基于全国人群癌症登记发病数据与国家卫生统计中心死亡数据,对卵巢癌发生情况进行概述并回顾早期检测策略。
主要发现
- 2018年美国预计新发卵巢癌22,240例、死亡14,070例。
- 总体发病率从1985年16.6/10万降至2014年11.8/10万,降幅29%。
- 死亡率从1976年10.0/10万降至2015年6.7/10万,降幅33%。
- 亚裔/太平洋岛民子宫内膜样癌与透明细胞癌发病率最高,发病年龄更年轻。
关键数值与推荐
- 多数浆液性癌诊断时为III期(51%)或IV期(29%),2007至2013年诊断者5年病因特异性生存分别为42%和26%。
- 所有分期上皮性癌合计5年生存率亚裔/太平洋岛民最高(57%),非西班牙裔黑人最低(35%)。
- 非西班牙裔黑人5年生存率从1992至1994年诊断的40%至2007至2013年诊断的47%未见改善,而同期非西班牙裔白人有所提高。
临床怎么用
- 临床认识卵巢癌组织学异质性,浆液性癌多在晚期诊断且生存率低。
- 关注非西班牙裔黑人几乎各分期生存最低且数十年未改善的种族差异。
- 重视亚裔/太平洋岛民子宫内膜样癌与透明细胞癌在较年轻年龄发病的特点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In 2018, there will be approximately 22,240 new cases of ovarian cancer diagnosed and 14,070 ovarian cancer deaths in the United States. Herein, the American Cancer Society provides an overview of ovarian cancer occurrence based on incidence data from nationwide population-based cancer registries and mortality data from the National Center for Health Statistics. The status of early detection strategies is also reviewed. In the United States, the overall ovarian cancer incidence rate declined from 1985 (16.6 per 100,000) to 2014 (11.8 per 100,000) by 29% and the mortality rate declined between 1976 (10.0 per 100,000) and 2015 (6.7 per 100,000) by 33%. Ovarian cancer encompasses a heterogenous group of malignancies that vary in etiology, molecular biology, and numerous other characteristics. Ninety percent of ovarian cancers are epithelial, the most common being serous carcinoma, for which incidence is highest in non-Hispanic whites (NHWs) (5.2 per 100,000) and lowest in non-Hispanic blacks (NHBs) and Asians/Pacific Islanders (APIs) (3.4 per 100,000). Notably, however, APIs have the highest incidence of endometrioid and clear cell carcinomas, which occur at younger ages and help explain comparable epithelial cancer incidence for APIs and NHWs younger than 55 years. Most serous carcinomas are diagnosed at stage III (51%) or IV (29%), for which the 5-year cause-specific survival for patients diagnosed during 2007 through 2013 was 42% and 26%, respectively. For all stages of epithelial cancer combined, 5-year survival is highest in APIs (57%) and lowest in NHBs (35%), who have the lowest survival for almost every stage of diagnosis across cancer subtypes. Moreover, survival has plateaued in NHBs for decades despite increasing in NHWs, from 40% for cases diagnosed during 1992 through 1994 to 47% during 2007 through 2013. Progress in reducing ovarian cancer incidence and mortality can be accelerated by reducing racial disparities and furthering knowledge of etiology and tumorigenesis to facilitate strategies for prevention and early detection. CA Cancer J Clin 2018;68:284-296. © 2018 American Cancer Society.
引用
- Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018. PMID: 29809280. doi:10.3322/caac.21456
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。